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2014, accepted Janver the last few years, the ﬁeld of microribonucleic acid (miRNA) in cardiovascular biology and disease has
expanded at an incredible pace. miRNAs are themselves part of a larger family, that of non-coding RNAs, the
importance of which for biological processes is starting to emerge. miRNAs are w22-nucleotide-long RNA
sequences that can legate messenger (m)RNAs at partially complementary binding sites, and hence regulate the
rate of protein synthesis by altering the stability of the targeted mRNAs. In the cardiovascular system, miRNAs have
been shown to be critical regulators of development and physiology. They control basic functions in virtually all cell
types relevant to the cardiovascular system (such as endothelial cells, cardiac muscle, smooth muscle,
inﬂammatory cells, and ﬁbroblasts) and, thus, are directly involved in the pathophysiology of many cardiovascular
diseases. As a result of their role in disease, they are being studied for exploitation in diagnostics, prognostics, and
therapeutics. However, there are still signiﬁcant obstacles that need to be overcome before they enter the clinical
arena. We present here a review of the literature and outline the directions toward their use in the clinic.
(J Am Coll Cardiol 2014;63:2177–87) ª 2014 by the American College of Cardiology FoundationAlthough protein-coding and transcription-regulating se-
quences occupy <3% of our genome, it seems that at least
75% is transcribed (1). A certain amount of the genome has
been known for some time to be dedicated also to encoding
infrastructural ribonucleic acid (RNA)dsuch as transfer,
ribosomal, and small nuclear and nucleolar RNAs (2)dbut
the fact that most of the genome did not seem to be func-
tional was a mystery to be resolved. It is now understood not
only that much of a cell’s transcriptome is involved in the
production of regulatory RNA species, but also that these
RNAs rival proteins in importance for the control of bio-
logical processes (3). Therefore, a vast part of our genome is
not dedicated to proteins but, rather, to the production of
non–protein coding RNAs (ncRNAs) with regulatory
functions. The ﬁrst eukaryotic ncRNA was reported in the
late 1980s (4), and since then their number has grown
steadily, with reports demonstrating novel roles in many
biological processes (5). A hint of the vital importance of
ncRNA for higher organisms is conveyed by the hypothesis
that eukaryotic complexity and phenotypic variation is
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uary 28, 2014.networkdof which ncRNA are a chief componentdrather
than merely the size of the protein repertoire (3).
Among the different types of ncRNA, the microRNA
(miRNA/miR) family has a central role in pathophysiolog-
ical response to stress (6), regulating at least half of the
transcriptome and constituting a layer of regulation that
works in concert with more conventional protein-mediated
mechanisms (7–9). miRNAs form an abundant ncRNA
species, with nearly 2,000 human miRNA sequences cata-
logued hitherto (10), although it is not clear if all are bona
ﬁde. Many of these miRNAs have tissue-speciﬁc and
developmental stage–speciﬁc patterns of expression (11).
microRNAs exert their function by regulating gene
expression at the level of messenger RNA (mRNA) trans-
lation: It is solidly established that they regulate speciﬁc
cellular processes through mRNA target recognition lead-
ing to the inhibition of protein synthesis. In particular, a
speciﬁc miRNA may target multiple mRNAs (divergent
miRNA pathway), a given mRNA may harbor binding sites
for different miRNA (leading to combinatorial control by
miRNAs), and sets of related miRNAs may affect a given
pathway at different levels (convergent miRNA pathway)
(Fig. 1). These characteristics create a 3-dimensional
miRNA–mRNA interactome (the set of interactions oc-
curring within a cell) that changes in relation to develop-
mental stage, age, and pathophysiological state of the cell
(12,13). A list of cardiovascular miRNAs and validated
mRNA targets has been reported in a recent extensive re-
view (14). It is possible, moreover, that they work also
through other regulatory mechanisms, such as within the
nucleus to regulate gene expression (15,16).
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2178Once bound to the target,
miRNAs can proceed to organ-
elles called P-bodies, which fuse
with endolysosomes. As a result,
miRNAs can either enter a deg-
radative pathway or, via the for-
mation of multivesicular bodies,
can be released into the extra-
cellular space and circulation
within small vesicles called exo-
somes (17). miRNAs can also be
secreted from cells as vesicular
bodies arising from the plasma
membrane or can be simply ex-
truded by cells through mem-
brane shedding. Moreover, some
cells, such as endothelial cells
(ECs), can release miRNAs
under the form of apoptotic
bodies (17). Thus, miRNAscan be found within the circulation either in a “free”
formdthat is, complexed with proteins, such as argonaute
2 or plasmatic proteinsdor within membrane-bound
bodies.
miRNAs in Myocardial Development and Disease
In 2002, 9 years after the description of the ﬁrst miRNA
in the nematode Caenorhabditis elegans by Lee et al. (18) and
Wightman et al. (19), Calin et al. (20) published the ﬁrst
report describing a pathogenic role for an miRNA, specif-
ically implicating deletion of the miR-15a/miR-16 cluster
in the development of chronic leukemia. Since then, many
other diseases have been linked with miRNA dysregulation,
and today the importance of miRNA-mediated post-tran-
scriptional regulation for the proper functioning of cardio-
vascular homeostasis, and the implications for heart disease
pathogenesis, diagnosis, and prognosis are well established
for the scientiﬁc community (21).
The role of miRNAs in myocardial development was ﬁrst
assessed in the fruit ﬂy Drosophila, in which it was deter-
mining that miR-1done of the most expressed miRNA
in cardiac muscledcontrolled the Notch 1 receptor (22).
A causal link was established between cardiac hypertrophy
and miRNAs by studying those preferentially expressed in
the heart (23). In particular, miR-208a was found to be
encoded by a gene residing within an intron of alpha-myosin
heavy chain, to be regulated during cardiac hypertrophy, and
to regulate this process itself by targeting a protein inter-
acting with thyroid hormone receptor (24). At the same
time, miR-1 and miR-133dwhich are encoded together in
a bicistronic unitdwere found to be inversely related to
cardiac hypertrophy and to regulate cardiomyocyte size and
function (25). miR-1 was found to modulate the insulin-like
growth factor-1 pathway either directly, inhibiting insulin-
like growth factor-1 and its receptor (26), or by down-regulating secreted targets related to this pathway (27).
The manipulation of miRNA levels with speciﬁc anti-sense
moleculesdcalled antagomiRs dwas proven to work efﬁ-
ciently in the myocardium in vivo and to induce signiﬁcant
cardiac effects (25). A direct link between miR-21 and the
miR-29 family with myocardial ﬁbrosis during hypertrophy
was also demonstrated (28,29), suggesting that miRNAs
control different components of myocardial remodeling.
Indeed, further studies demonstrated that miRNAs control
fundamentally all critical aspects of cardiovascular biology,
such as angiogenesis (30), metabolism (31–34), aging (35),
and also the inﬂammatory component of myocardial
remodeling: for instance, miR-155 was found to control
macrophage activity, thereby regulating cardiac hypertrophy
through an indirect, inﬂammation-dependent mechanism
(36).
The involvement of miRNAs in human cardiomyopathies
has also been suggested. For example, a rare mutation of
miR-499da muscle-speciﬁc miRNAdwas found at its 30
end, outside the seed region thought to determine target
recognition; this mutation was able to modify mRNA tar-
geting and end-organ function, leading to heart failure (HF)
in mice (37).
Very recently, exogenous administration of miRNAs, in
particular miR-590-3p and miR-199a-3p, was found to
enhance cardiomyocyte proliferation in newborn pups and
in adult mice within the peri-infarct area (38). These results,
if conﬁrmed, imply that miRNAs could restore left ven-
tricular mass and promote functional recovery after myo-
cardial infarction (MI).
miRNAs in Vascular Diseases
As for the ﬁeld of cardiology, that of vascular pathophysi-
ology has seen an explosion of studies on miRNAs. miRNA
were clearly demonstrated to play a fundamental role in
controlling smooth muscle cell proliferation and maturation,
vasculogenesis, neoangiogenesis, bone marrow cells, and
endothelial function. We will brieﬂy review some of the
most critical discoveries in vascular biology.
In EC dysfunction, the differential expression of miR-10a
was found to contribute to the regulation of the proin-
ﬂammatory EC phenotype in atherosusceptible regions by
inhibiting proinﬂammatory adhesion molecules, such as
vascular cell adhesion molecule (CAM)-1, E-selectin, or
the NF-kB pathway; similarly, miR-181, miR-126, miR-31,
and miR-17-3p control vascular inﬂammation, acting
on the expression of vascular CAM-1, intracellular CAM-1,
and E-selectin (39–41). Cholesterol is a pivotal player
not only in atherosclerosis development but also in metabolic
syndrome and diabetes mellitus (DM). All the processes
involved in the maintenance of cholesterol levels, such as
de novo biosynthesis, internalization of exogenous choles-
terol, and removal of its excessive cellular levels by high-
density lipoproteins, are controlled at least partially
by miRNAs. Two miRNAs have been implicated the most
Figure 1 Schematic of miRNA Biogenesis and Function
Microribonucleic acids (miRNAs) derive from primary miRNAs (pri-miRNAs), of
many hundreds or thousands of nucleotides in length, which are folded into
characteristic hairpin structures. Over 50% of all miRNAs are polycistronic, that is,
they are generated from a common transcript or a gene cluster, which is thought to
efﬁciently allow cooperative miRNAs to be expressed simultaneously even when
not part of the same miRNA family (i.e., when they do not have the same seed
sequence). In the canonical miRNA biogenesis pathway, pri-miRNAs are cleaved in
the nucleus by the ribonuclease drosha to form shorter, 70 to 100-nucleotides-
long, preliminary miRNAs (pre-miRNAs), which are then transported out of the
nucleus. In the cytoplasm, pre-miRNAs are recognized by another ribonuclease,
dicer, and processed into short, double-stranded, immature miRNA. The strand
with the 50 terminus that has less-stable base-pairing is stripped away from the
duplex and transferred to argonaute 2 (AGO2). In addition to the canonical miRNA
biogenesis pathway, others have been uncovered. miRNAs function as guides for a
type of ribonucleoprotein called an miRNA-induced silencing complex (miRISC): the
miRNA incorporated into each miRISC targets messenger RNAs (mRNAs) that
harbor partially complementary binding site(s) to the targeting miRNA(s). Once
bound to miRNA, the mRNA is negatively regulated through the action of the
protein components of the miRISC. In mammals, miRNA-mediated negative
regulation of protein synthesis probably occurs predominantly through mRNA
destabilization rather than translation repression, but the mechanisms through
which the miRISC acts remain to be fully elucidated. In any case, it is thought that
the ultimate outcome of most mammalian miRNAs is <2-fold ﬁne-tuning of their
targets’ expression. A primary determinant of miRNA–mRNA interaction is thought
to be perfect Watson–Crick base-pairing of nucleotides 2 to 8 (called the seed
region) at the 50 end of the miRNA, to nucleation sites typically present on the
30 untranslated region (UTR) of the targeted mRNA. miRNAs can also be secreted
by cells through exosomes, apoptotic bodies, and other vesicular-like bodies.
In this way, miRNA-mediated signals can be transferred to surrounding and/or
distant cells/tissues. This phenomenon could be exploited for diagnostic/
prognostic purposes by assessing the miRNA proﬁle in biological ﬂuids.
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2179in lipid homeostasis: miR-122 and miR-33. miR-122
is mainly expressed in liver and was the ﬁrst miRNA
described as a regulator of lipid metabolism (42,43).Antagonists of miR-122 resulted in a lowering of total
cholesterol (both high- and low-density lipoproteins) and in
an improvement of hepatic steatosis (42). Members of the
miR-33 family, which includes miR-33a and miR-33b, have
been found as intronic RNAs in sterol regulatory element-
binding proteins and, being co-transcribed with their host
genes, have been proposed as key regulators of cholesterol
and fatty acid homeostasis (44–46).
In the intima, low-density lipoprotein uptake and in-
ﬂammatory modulation in macrophages were also found
controlled by miRNAs, such as miR-155 (47) and miR-
125a-5p (48). Vascular smooth muscle cell (VSMC) pro-
liferation in the neointima is responsible for the evolution
from fatty streaks to ﬁbrous atheroma, and an epigenetic
mechanism mediated by miR-29b can regulate metal-
loproteinase expression involved in cell migration and
VSMC proliferation, such as metalloprotein-2 and -9 genes
(49). Moreover, the switch from the contractile to a
secretory phenotype can be modulated by miR-145, which
is highly expressed in VSMCs: VSMC-targeted miR-145
treatment markedly reduced plaque size in aortic sinuses,
increasing the ﬁbrous cap area, reducing the necrotic core
area, and increasing plaque collagen content, and thus pro-
moting a contractile VSMC phenotype. Therefore, VSMC-
speciﬁc overexpression of miR-145 could be a promising
novel therapeutic strategy for the stabilization of athero-
sclerotic plaque morphology and cellular composition,
shifting the balance toward plaque stability and away from
plaque rupture (50). Cholesterol-loaded macrophages are
partly in charge of the cytokine synthesis that promotes
neoangiogenesis: this process is mediated by miR-222/221
(51) and miR-155: miR-155 promotes atherosclerosis by
repressing B-cell lymphoma 6 protein in macrophages (52).
miR-342-5p fosters inﬂammatory macrophage activation
through an AKT1- and miR-155–dependent pathway
during atherosclerosis (53).
Expression of the miR-17w92 cluster is regulated by
vascular endothelial growth factor, and, therefore, its role in
regulating neoangiogenesis appears pivotal, although com-
plex and not yet completely elucidated (54). Neoangio-
genesis and intraplaque hemorrhage are the major steps in
promoting plaque vulnerability, leading to plaque destabi-
lization, rupture, and thrombus formation. Thus, the sig-
niﬁcant miRNA involvement in this setting needs to be
clariﬁed. Taken together, these ﬁndings emphasize the
potential beneﬁcial effects of up-regulation of atheropro-
tective miRNAs and down-regulation of proatherogenic
ones, but we are still far from the direct translation of
research into a concrete therapeutic strategy.
VSMC Differentiation and Proliferation in
Cardiovascular Diseases
The most studied miRNAs expressed by VSMCs belong
to the miR-143/145 cluster, which has a pivotal role in
VSMC differentiation and arterial pathogenesis (55–58).
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2180The expression of miR-143/145 is decreased by acute
and chronic vascular stresses (such as transverse aortic
constriction and apolipoprotein E knockout-induced
atherosclerosis); in human aortic aneurysms, the expression
of miR-143/145 is signiﬁcantly decreased compared with
control tissue (58). Phenotypic modulation of VSMCs has
been implicated in the pathogenesis of various proliferative
vascular diseases, and miR-145 is able to control vascular
neointimal lesion formation through its target Kruppel-like
factor 5 and its downstream signaling molecule myocardin
(59). Up-regulation of miR-145, but not of miR-143, was
observed in pulmonary artery VSMCs and in lung tissue
from patients with idiopathic and heritable pulmonary
arterial hypertension, a pathology characterized by extensive
remodeling of small pulmonary arteries and proliferation of
pulmonary artery VSMCs (60). Other studies highlighted
the regulatory role of miR-221 and miR-222 in VSMC
proliferation and neointimal hyperplasia, showing that miR-
221/222 down-regulation resulted in decreased VSMC
proliferation in vitro and in rat carotid arteries (61). More
recently, miR-663 was found down-regulated in human
aortic VSMCs upon treatment with platelet-derived growth
factor, and to be in charge of VSMC phenotypic switching
by targeting JunB/myosin light chain 9 expression (62).
Similarly, miR-133 plays a modulatory role in VSMC
phenotypic switching in that it decreases when VSMCs are
primed to proliferate in vitro and following vascular injury
in vivo, whereas it increases when VSMCs are coaxed back
to quiescence (63).
Peripheral Ischemia and
Vascular Consequences of DM
The conserved miR-17w92 clusterdwhich comprises
miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and
miR-92adwas found highly expressed in human ECs, and
in particular overexpression of miR-92a blocked EC
angiogenesis in vivo and in vitro, whereas administration of
its antagomiR in mouse models of limb ischemia and
myocardial infarction led to enhanced blood vessel growth
and functional recovery of damaged tissues (64). Adminis-
tration of bone-derived mononuclear cells in infarcted mu-
rine hearts reduced proapoptotic miR-34a expression in the
infarct border zone, which is probably related to a paracrine
effect because bone-derived mononuclear cell supernatants
blocked H2O2-induced expression of miR-34a in car-
diomyocytes in vitro (65); vice versa, reduced expression of
miR-34a improved the survival of mononuclear cells in vitro
and enhanced the therapeutic beneﬁt of cell therapy in
infarcted mice (66). In addition, the microangiopathy and
damaging effects of DM were demonstrated in bone-
marrow stem cells of diabetic patients, including microvas-
cular rarefaction and shortage of progenitor cells, attributable
to activation of a proapoptotic pathway regulated by
miR-155 (67). DM also impaired circulating proangiogenic
cells supporting post-ischemic neovascularization, throughmiR-15a and miR-16 regulation (68). These miRNAs are
also found in the serum upon chronic limb ischemia, and
positively correlated with amputation after restenosis at
12 months post-revascularization in DM patients (68).
Again in DM patients, miR-503 was found up-regulated
in ECs and plasma (69).
Circulating miRNAs:
New Biomarkers of Cardiovascular Diseases?
miRNAs are remarkably stable in the extracellular milieu,
and they are detectable in blood and other body ﬂuids. In
fact, circulating miRNAs are shielded from RNA-degrading
enzymes either because of association in an extra-vesicular
state with lipoproteins (high-density lipoprotein) (70,71)
or protein (argonaute 2) complexes (72); or because they
are found within vesicles, such as microparticles (73), exo-
somes (74,75), and apoptotic bodies (76). In particular,
microparticles play a key role in a communication network
for the local and systemic intercellular exchange of biological
information, and harbor a speciﬁc concentrated set of cy-
tokines, signaling proteins, mRNAs, and miRNA that can
be effectively transferred to recipient cells (77). In fact, it has
been suggested that miRNAs released from 1 cell type can
be taken up by another in which they can then act: for
instance miR-126 is contained in apoptotic bodies taken up
by VSMCs, improving survival of the latter (76); similarly,
miR-143 expression in ECs was found to be up-regulated by
KFL2 and taken up by adjacent VSMCs, improving their
functionality (78).
Interestingly, circulating miRNAs share many of the
essential characteristics of a good biomarker: noninvasive
measurability; a high degree of sensitivity and speciﬁcity,
allowing early detection of pathological states; time-related
changes during the course of disease; a long half-life within
the sample; and rapid and cost-effective laboratory detection.
miRNAs may fulﬁll most of these criteria. However, anti-
coagulation (79) and antiplatelet (80) drugs can affect quan-
tiﬁcation of miRNAs in blood samples, and must be taken
into account when assessing circulating miRNAs (81).
Since their discovery in the circulation (82), the potential
use of miRNA as serum biomarkers has been intensely studied
(83,84). The value of currently available cardiovascular bio-
markers in clinical practicedwhich are usually proteins or
polypeptidesdcould be enhanced by the use of novel molec-
ular and genetic biomarkers and improvements in risk pre-
diction algorithms, with the ultimate goal of developing
personalized medicine based on “omics” sciences. The use of
these novel biomarkers for the prediction of cardiovascular-
disease risk before clinical onset is appealing (84). Several
groups have proposed circulating miRNAs as biomarkers for
diagnosis and prognosis of cardiovascular pathologies ranging
from HF (85), acute MI (86–89), and cardiomyopathies
(90,91) to atherosclerosis (92) and DM (93). Despite their
promise, miRNAs still have not entered the clinical scenario,
mainly because of a lack of large cohort studies.
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2181Another limitation to account for is related to the use of
polymerase chain reaction technology: miRNA sequences
are ampliﬁed using oligonucleotides speciﬁc for small nucleic
acids. However, this ampliﬁcation step may lead to artifacts
if not properly titrated and conducted without rigorous
controls. Recent advances are improving the precision of
miRNA dosage: digital polymerase chain reaction is based
on ampliﬁcation of molecules diluted to the point that 1
single miRNA molecule is included per reaction (94,95);
direct nucleic acid sequencing is another, very efﬁcient,
though still expensive, technique for accurately measuring
RNAs (96). In large screening efforts, the cost of the study is
obviously a limiting issue.
Heart failure. A unique miRNA signature for HF has not
been identiﬁed yet (Table 1). miR-423-5p was found
signiﬁcantly increased in HF patients (97,98), but neither
miR-423-5p nor miR-133a were associated with the level of
brain-type natriuretic peptide, left ventricle function, or
cardiac remodeling (99). In patients with acute HF, only
miR-499 was signiﬁcantly elevated (2-fold), with no signif-
icant changes in the other mRNAs studied in patients with
diastolic dysfunction (100). More recently, miR-519e*, miR-
520d, miR-1231, miR-200b*, miR-622, and miR-1228*
were found increased and correlating with brain-type natri-
uretic peptide levels in non-ischemic systolic HF (85).
Cardiac hypertrophy. Twelve circulating miRNAs were
found signiﬁcantly elevated in hypertrophic cardiomyopathy
patients, but only 3 (miR-199a-5p, miR-27a, and miR-29a)
correlated with hypertrophy; in particular, miR-29a was
signiﬁcantly associated with both hypertrophy and ﬁbrosis
evaluated with cardiac magnetic resonance, identifying it as aTable 1 Some Circulating miRNAs Found Associated With the Enlarg
miRNA Misexpression Specimen
Heart failure
miR-423-5p, miR-320a,
miR-22, miR-92b
Up-regulated in systolic
HF patients
Serum
miR-126 Negatively correlated with age
and NYHA functional class
in HF patients
Plasma
miR423-5p Up-regulated in HF patients Plasma
miR-192, miR-194, and
miR-34a
Up-regulated at early stage of
post-ischemic HF
Serum
miR-200b*, miR-622,
miR-1228*
Up-regulated in HF in patients
with reduced ejection fraction
Whole blood
and serum
miR-210, miR-30a Up-regulated in HF patients Serum
Hypertrophic cardiomyopathy
miR-29 Up-regulated in HCM patients,
biomarker of hypertrophy
and ﬁbrosis
Plasma
Dilated cardiomyopathy
miR-548c Down-regulated in PBMCs from
DCM patients
Whole blood
AMI ¼ acute myocardial infarction; CCU ¼ coronary care unit; DCM ¼ dilated cardiomyopathy; ED ¼
microribonucleic acid; NYHA ¼ New York Hear Association; PBMC ¼ peripheral blood mononuclear cell.potential biomarker for myocardial remodeling assessment
in hypertrophic cardiomyopathy (91).
Acute myocardial infarction and acute coronary syndrome.
In patients with acute MI, miR-1, miR-133a, miR-499,
and miR-208a have been reported up-regulated in plasma
as a result of cardiomyocyte necrosis and massive release into
the bloodstream (Online Table 1) (86,87,101,102). The time-
dependent release of acute MI-related miRNAs has been
recently investigated: miR-1, miR-133a, and miR-208a
increased continuously during the ﬁrst 4 h after the induc-
tion of MI (103), before conventional biomarkers of acute MI
could be detected. In a study comparing human and murine
circulating miRNAs, human miR-1, miR-133a, and miR-
133b peaked before cardiac troponin T (cTnT), whereas
murine miR-499 appeared to be a more sensitive marker of
acute MI in mice (89). miR-1 and miR-133a were increased
in patients with acute MI, unstable angina, or Takotsubo
cardiomyopathy (104). The circulating levels of miR-499 and
miR-208b have been correlated with cTnT values in car-
diopathic patients (100), and circulating miR-133a has been
correlated with prognostic magnetic resonance markers, such
as infarct size, microvascular obstruction, and myocardial
salvage index, but was unable to independently predict clinical
events (105). miR-133a was also substantially increased in
patients with acute MI relative to those with Takotsubo
cardiomyopathy: in fact, a unique signature comprising miR-1,
miR-16, miR-26a, and miR-133a differentiated Takotsubo
cardiomyopathy patients from healthy subjects and from acute
MI patients (106). miR-208a has been proposed as a novel
biomarker because it becomes detectable in plasma within 1 to
4 h from symptoms onsetdwhen cTNT is still below theed Heart
Study Population Setting Ref. #
30 stable chronic HF patients þ
30 controls
Hospital admission (98)
10 congestive HF patients þ
17 controls
Hospital admission (117)
50 patients with dyspnea
(30 HF patients and 20 non-HF
patients) þ 39 controls
Hospital admission (118)
65 post-AMI patients and
65 controls
CCU (119)
53 nonischemic HF patients
and 39 controls
Hospital admission (85)
22 HF patients and 18 controls þ
9 pregnant women
Hospital admission (120)
41 HCM patients þ 41 controls Hospital admission (121)
44 stable chronic HF þ 48 controls Hospital admission (90)
emergency department; HCM ¼ hypertrophic cardiomyopathy; HF ¼ heart failure; miRNA/miR ¼
Figure 2
Schematic of Hypothetical miRNA-Based
Therapeutic Strategies
miRNA(s) found to have a role in pathogenesis and that are overexpressed during
diseased states can be targeted for sequestration through the administration of
anti-miRNAs, such as cholesterol-conjugated antisense oligonucleotides called
antagomiRs, which compete with the cognate mRNA target(s). In this way,
inappropriately down-regulated mRNAs return to normal levels of expression.
In contrast, disease–down-regulated miRNAs may, in theory, be replenished
through the administration of double-stranded oligonucleotides that contain the
miRNA sequence. These are designed to co-opt the miRNA biogenesis
machinery for maturation and incorporation of the artiﬁcial miRNA into the miRISC.
Abbreviations as in Figure 1.
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2182cut-off valuedbecause it is cardiac-speciﬁc, and because it is
absent in healthy subjects and patients without acute MI
(86,107). However, the prognostic impact of circulating
miRNAs (miR-1, miR-133a, miR-133b, miR-208a, miR-
208b, and miR-499) in acute MI is still debated because a
sizeable overlap exists between patients with unstable angina
(108). Therefore, the current clinical use of miRNAs as
biomarkers for these pathologies is still limited, with other
biomarker analyses (such as high-sensitivity cTnT) being
currently more easily conducted than the quantitative poly-
merase chain reaction-based assays needed to assess circulating
miRNAs.
More recently, the prognostic value of circulating
miRNAs has been evaluated. Despite the time-dependent
changes in circulating miR-133a and miR-423, none
were associated with indices of left ventricular function
and remodeling or with brain natriuretic peptide (99). miR-
208b was found to be a modest but signiﬁcant predictor
of 6-month mortality, but, along with miR-499 and high-
sensitivity cTNT, was not a signiﬁcant predictor of 6-year
mortality in a cohort of 510 patients (109). To assess the
association with incident MI and circulating miRNAs,
a prospective study on a total of 19 miRNAs was con-
ducted: miR-223 and miR-197 showed negative associa-
tions, while miR-126 showed a positive association with
subsequent acute MI (88). miR-126, a pivotal regulator of
endothelium and vascular integrity, is mostly abundant
in platelets, but its role is still under debate (110).
Vascular consequences of DM. In a population-based
study, miR-126 appeared inversely correlated with DM
and its severity (93), and thus might have diagnostic and
prognostic implications. Loss of miR-126 could be the result
of altered secretion, degradation, or cellular uptake. Another
study revealed that 7 miRNAs involved in insulin biosyn-
thesis and secretion were signiﬁcantly up-regulated in DM
patients (111). More recently, miR-146a was found signif-
icantly elevated in newly diagnosed DM patients, but no
prognostic value could be found (112).
Therapeutic Perspective on miRNAs in
Cardiovascular Diseases
The therapeutic use of miRNAs is currently being explored
through 2 approaches: overexpression and inhibition
(Fig. 2). The chemistry behind gene inhibition through
antisense methodologies is signiﬁcantly more advanced than
miRNA overexpression through mimicry: whereas an
increased miRNA number can be achieved through the use
of viral vectors, oligonucleotide miRNA mimics are still
under development. It is difﬁcult, though, to foresee the
application of viral vector-mediated gene expression. On
the other hand, antisense oligonucleotides can be used to
efﬁciently inhibit miRNAs. These antisense sequences need
to be modiﬁed in order to improve their stability and tissue
distribution. Since miRNAs can bind to targets with
different sequences, and sequences outside the seed regionmay be biologically active, anti-miRNAs may have a “pro-
miscuous” effect. Thus, a rigorous approach is needed to
assess their on-target effect on diseased tissues. Off-target
effects are highly likely to occur when doses are increased.
Reference (113) is a detailed extensive review on pharma-
cokinetics and pharmacodynamics of anti-miRNAs.
Anti-miRNAs are chemically modiﬁed to improve
binding afﬁnity, nuclease resistance, and cellular uptake.
High-afﬁnity interaction of antisense oligonucleotides with
miRNAs is achieved through chemical modiﬁcations that
enhance binding afﬁnity and confer nuclease resistance and
protein binding (phosphorothioate backbone linkages), and
facilitate cellular uptake (20-O-methyl-cholesterol-conjuga-
tion) (114). It has been demonstrated that they are efﬁciently
taken up by cells of the cardiovascular system, including
cardiomyocytes, ECs, and ﬁbroblasts, and exert a potent
biological effect within this context.
Anti-miRNAs can have different lengths: antagomiRs
are antisense molecules of the whole miRNA sequence;
they have phosphorothioate backbone modiﬁcations and are
conjugated with (20-O-methoxy)cholesterol (115). Locked
Table 2 Effects of the Administration of Some miRNAs and Anti-miRNAs on the Cardiovascular System in Animal Models
miRNA Type Species Therapeutic Effect Ref. #
Post-myocardial infarction remodeling
miR-15 family Locked nucleic acid
(LNA)-modiﬁed anti-miRNA
Mice and pigs Reduced infarct size and cardiac remodeling
and enhances cardiac function in response to MI
(122)
miR-24 2-O-methyl-linked and
3-cholesterol-linked antagomiR
Mice Reduced infarct size, improved vascularity
and cardiac performance after ischemic injury
(123)
miR-320 AntagomiR Mice Reduced infarct size via antithetical regulation
of heat-shock protein-20
(124)
miR-29b 20 -O-methyl-linked and
30 -cholesterol-linked mimics
Mice May reduce increase in ﬁbrosis after MI (29)
miR-590 and
miR-199a
Transfection with human
miR-590-3p and miR-199a-3p
Mice Reduced infarct size and improved cardiac function,
consistent with the effect of these miRNAs in
actively stimulating cardiomyocyte proliferation
(38)
Cardiac remodeling, cardiac hypertrophy, and ﬁbrosis
miR-208a LNA-modiﬁed anti-miRNA Dahl rats Reduction in cardiac remodeling with improvement
in cardiac function
(125)
miR-212/132 family miR-212/132 knockout
mice with TAC
Mice Protection from pathological cardiac hypertrophy
induced by pressure overload via TAC
(126)
miR-133 antagomiR-133 Mice Induction of a sustained cardiac hypertrophy (25)
mIR-21 20 -O-methyl and 30 -cholesterol
antagomiR
Mice Reduced cardiac ﬁbrosis, leading to enhance
cardiac function in response to pressure overload
(28)
miR-21 LNA-modiﬁed anti-miRNA
oligonucleotide
Mice Failed to block the ventricular remodeling
response to stress
(127)
Atrial ﬁbrillation
miR-328 20 -O-methyl and 30 -cholesterol
antagomiR
Mice and
dogs
Rescue from the atrial ﬁbrillation phenotype and
the associated atrial remodeling properties
(128)
Atherosclerosis
miR-145 Adenoviral overexpression and
20 -O-methyl antagomiR
Rat Regulated vascular SMC phenotype and controlled
vascular neointimal lesion formation
(59)
miR-145 Lentiviral overexpression Mice Promoted a contractile phenotype in vascular SMC
and reduced plaque size
(50)
miR-21 20 -O-methyl antagomiR Rat Decreased vascular SMC proliferation and increased
apoptosis
(129)
miR-33 LNA-antisense oligonucleotides Mice Elevated HDL cholesterol (44)
miR-33 anti-miRNA Non-human
primates
Raised HDL cholesterol and lowered VLDL cholesterol (130)
miR-122 20 -O-methoxyethyl phosphorothioate
antisense oligonucleotide
Mice Decreased plasma HDL and LDL cholesterol levels
and improved liver steatosis
(42)
miR-122 LNA-anti-miRNA Non-human
primates
Decreased total plasma cholesterol without any
evidence for LNA-associated toxicity
(43)
miR-126 miR-126 enriched in apoptotic bodies Mice Stabilized and decreased size of atherosclerotic lesions (76)
Aneurysm
miR-29b LNA-anti-miR-29b Mice Increased collagen expression, reducing abdominal
aortic aneurysm progression
(131)
miR-29b LNA-anti-miR-29b Mice Induced extracellular matrix expression and inhibited
angiotensin II-induced dilation of aortic aneurysm
(132)
Angiogenesis
miR-92a 20 -O-methyl-linked and
30 -cholesterol-linked antagomiR
Mice Enhanced blood vessel growth and functional recovery
of ischemic tissue
(64)
miR-23/27 LNA-anti-miRNA Mice Repressed angiogenesis in a laser-induced choroidal
neovascularization model
(133)
miR-24 2prime;-O-methyl-linked and
30 -cholesterol-linked anti-miRNA
Mice Prevention of endothelial apoptosis and enhancement
of vascularity after MI
(123)
miR-503 adenovirus-mediated transfer of
miR-503 decoy
Mice Corrected diabetes mellitus-induced impairment of
post-ischemic angiogenesis and blood ﬂow recovery
(69)
Pulmonary hypertension
miR-145 LNA-anti-miRNA Mice Prevented the development of pulmonary artery hypertension (60)
Stroke
miR-320a LNA-antimiR-320a Rats Reduced cerebral edema and infarct volume in cerebral ischemia (134)
Acute myocarditis
miR-155 LNA-anti-miRNA Mice Attenuated cardiac inﬁltration, decreased T lymphocyte activation,
and reduced myocardial damage
(135)
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; LNA ¼ alpha-linolenic acid; MI ¼ myocardial infarction; SMC ¼ smooth muscular cell; TAC ¼ transverse aortic constriction; other abbreviations
as in Table 1.
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2184nucleic acids are 8- or 15-base-long antisense molecules
with 20 sugar modiﬁcations (20-ﬂuoro and 20-O-methox-
yethyl groups), which confer a very high afﬁnity for the
target sequence. These molecules are for all intents and
purposes drugs: their efﬁcacy needs to be titrated against
their toxicity, which can lead to off-target effects, including
interference with gene expression in non-diseased tissues.
In addition, the use of locked nucleic acids has been sug-
gested to induce interference with the complement cascade
and activation of innate immunity, and hepatotoxicity has
been described in some reports (113).
The antisense approach has been used for therapeutic
purposes with a high degree of success in the con-
text of experimental myocardial hypertrophy and HF,
atherosclerosis, arterial restenosis, and dyslipidemia
(Table 2). However, the use of anti-miRNA in the cardio-
vascular arena is still in the pre-clinical phase. To date, only
1 antagomiR, anti-miR-122, has made it through to a
phase-II clinical trial for the treatment of hepatitis C virus
infection (116). Large-animal studies and phase I/II trials
on humans are still lacking for cardiovascular medicine.
Obstacles still need to be overcome before miRNAs can
become a therapeutic option in the near future, such as
the development of effective animal models, more precise
regulation of miRNA mimics, and antagonists that take into
account different individual cardiovascular risk factors and
age-related issues. Despite these obstacles, the road ahead
looks incredibly appealing: besides the knowledge that will
be generated by the understanding of the basic mechanisms
of cardiovascular pathogenesis, the possibility to develop new
diagnostic and therapeutic tools in this sector of medicine is
at hand.
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